AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04101409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aids
Description: Shared decision making with decision aids
Study NCT03856801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Whole-body vibration training in hypoxia and normoxia condition
Study NCT01755598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational TB vaccine (GSK692342)
Description: 2 doses administered intramuscularly in the deltoid region of the arm.
Study NCT03301649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Ivermectin Lotion 0.5%
Description: Topical lotion, generic formulation of the brand product.
Study NCT03301649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sklice® (Ivermectin) Lotion 0.5%
Description: Topical lotion, brand product.
Study NCT01755598 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses administered intramuscularly in the deltoid region of the arm.
Study NCT03219216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Film-coated tablet
Study NCT03301649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Description: Topical lotion, placebo. Has no active ingredient.
Study NCT02574832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Administration
Description: The lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). Two outcomes will be possible: satisfactory or unsatisfactory anesthesia.
Study NCT04113577 — intervention group
Intervention type: OTHER
Intervention: usability survey
Description: usability survey composed of subpart: System Usability Scale, questions about global ergonomics of the app, questions about eronomics of the exerecices, question about global satisfaction.
Study NCT00814476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medtronic CareLink therapy management system
Description: At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
Study NCT00814476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular home use and Medtronic CareLink Therapy Management
Description: At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.
Study NCT02922127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ulipristal Acetate
Description: Daily use of Ulipristal Acetate
Study NCT02922127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Combined Oral Contraceptive Pill
Description: Daily use of Oral Contraceptive Pill
Study NCT01007669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity and Health check
Description: Strength training, aerobic capacity training.
Study NCT01007669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health check only
Description: Health check
Study NCT01068145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Very low dose SCH 527123, once daily for 7 days
Study NCT01068145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Low dose SCH 527123, once daily for 7 days
Study NCT01068145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Medium dose SCH 527123, once daily for 7 days
Study NCT01068145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: High dose SCH 527123, once daily for 7 days
Study NCT01068145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to match SCH 527123, once daily for 7 days
Study NCT01068145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Low dose capsule SCH 527123, once daily for 14 days
Study NCT01068145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Medium dose capsule SCH 527123, once daily for 14 days
Study NCT01068145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: High dose capsule SCH 527123, once daily for 14 days
Study NCT01068145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to match SCH 527123, once daily for 14 days
Study NCT04552353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaway
Description: Drug: Voriconazole. Pharmacokinetic study under fasting conditions
Study NCT04552353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaway
Description: Drug: Voriconazole. Pharmacokinetic study under fasting conditions
Study NCT04762004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal speech
Description: In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
Study NCT04762004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal singing
Description: In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
Study NCT04762004 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: the newborn was placed by the nurse in the incubator in the standard care conditions recommended for painful procedures (supine position, wrapped and contained by the nest).
Study NCT01943383 — intervention group
Intervention type: GENETIC
Intervention: iPSC
Description: Single blood draw for the production of induced pluripotent stem cells.
Study NCT01757275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Na
Description: Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
Study NCT01757275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine
Description: Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
Study NCT01757275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Mg
Description: 40 mg tablet once daily for 27 days
Study NCT03774355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG1801
Description: Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.
Study NCT03774355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGL1802
Description: Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2
Study NCT03955458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: FICB with EXPAREL + Bupivacaine HCL (single dose)
Study NCT03955458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: FICB with continuous infusion of ropivacaine
Study NCT03955458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: FICB with EXPAREL + Bupivacaine HCL (Single dose)
Study NCT00613171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI571
Description: STI571 tablets taken orally once a day
Study NCT00714116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: Single IV or SC dose of SBI-087
Study NCT01220271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally
Study NCT00191126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2, IV, day 1 and 8, q 21 days x 3 cycles
Study NCT00191126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, IV, q 21 days x 3 cycles
Study NCT00191126 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: surgery
Study NCT00191126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: surgery
Study NCT03027960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 10mg empagliflozin for a 2-week period
Study NCT03027960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: 10 mg placebo for a 2-week period
Study NCT02770482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: spinal fluid collection
Study NCT01937871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Tadalafil
Description: Administered orally
Study NCT01937871 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Administered orally
Study NCT01937871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT01937871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01937871 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.2 mg Tamsulosin
Description: Administered orally
Study NCT04500717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib
Description: Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT04500717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib plus carboplatin and pemetrexed
Description: Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Study NCT03399513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib Oral Capsule [Imbruvica]
Description: Imbruvica 140 mg hard capsules (Active substance: Ibrutinib)
Study NCT03399513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOEP chemotherapy
Description: Immunochemotherapy
Study NCT04061239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.
Study NCT04061239 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daunorubicin
Description: Daunorubicin is commercially available as a powder for reconstitution in 20 mg vials. In this trial, daunorubicin should be administered as an IV infusion over 60 min.
Study NCT04061239 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Cytarabine is commercially available as vials/bottles for preparation of diluted infusion solution. Cytarabine will be administrated intravenously. In this trial, cytarabine is administered as a continuous infusion.
Study NCT04061239 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine
Description: Azacitidine at 75mg/m² for 7 days. Patients should receive a minimum of 2 and up to 6 cycles.
Study NCT05175703 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Passeo-18 Lux Paclitaxel releasing Balloon Catheter
Description: collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.
Study NCT01220271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Administered as approved
Study NCT01220271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally
Study NCT03173716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definity
Description: Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm
Study NCT01234233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: duration of preoperative active warming
Description: duration of prewarming by forced air warming
Study NCT03099551 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group using manual toothbrush Curaprox 5460 Ultra Soft
Description: Manual toothbrush usage with Bass technique twice a day during 2 minutes
Study NCT03099551 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group using sonic toothbrush Edel White
Description: Sonic toothbrush usage twice a day during 2 minutes
Study NCT03123224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Exercise + Caregiver Skills Training
Description: The combined moderate to high intensity combined aerobic and resistance exercise training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
Study NCT03123224 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Balance and Flexibility + Caregiver Skills Training
Description: The stretching, balance and flexibility training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
Study NCT01260259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: RIPC will be elicited in the operating room (OR) after anesthesia induction and before start of surgery. After placement of an arterial line, a tourniquet will be placed over a lower extremity. It will be inflated to 15 mmHg above systolic blood pressure for 5 minutes, and then deflated for 5 minutes. This cycle of inflation-deflation will be repeated another 3 times before surgery.
Study NCT01260259 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: In OR, after induction of general anesthesia and arterial line placement, a deflated tourniquet will be placed over the lower extremity for 40 minutes.
Study NCT01441596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course
Study NCT01441596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's choice of treatment
Description: Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
Study NCT03682913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-CIT protocol
Description: Personalized inhibitory control training for one week.
Study NCT03682913 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: without personalized inhibitory control training for one week.
Study NCT03223376 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: fruquintinib +paclitaxel
Description: treatment arm(fruquintinib +paclitaxel)- subjects will receive Fruquintinib orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
Study NCT03223376 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: fruquintinib placebo + paclitaxel
Description: control arm(fruquintinib placebo + paclitaxel)- subjects will receive Fruquintinib placebo orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
Study NCT01822392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Parent Management Training (Interactive)
Study NCT01822392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Parent Management Training (Recorded)
Study NCT02816528 — intervention group
Intervention type: BEHAVIORAL
Intervention: Training program
Description: Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
Study NCT03533244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% AG-86893 Eye Drops
Description: One drop, three times daily to the study eye for 28 days
Study NCT03533244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% AG-86893 Eye Drops
Description: One drop, three times daily to the study eye for 28 days
Study NCT03533244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Eye Drops
Description: One drop, three times daily to the study eye for 28 days
Study NCT01886703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer Walking Program
Description: All subjects will be prescribed a low-intensity walking program based on their current activity level and an daily assigned step count goal (with the current physical activity recommendations of 30 minutes of moderate-to-vigorous activity per day or 150 minutes per week as the ideal goal). Participants will be provided with face-to-face counseling and written material describing their specific individualized walking program. Participants will also be instructed to maintain their normal activities as much as possible during the intervention period. Participants will be given a pedometer and instructed to wear it at least 5 days per week for the duration of the study.
Study NCT02523573 — intervention group
Intervention type: PROCEDURE
Intervention: Adult ARF ICU patients needing BAL with HFNC
Description: bronchoalveolar lavage is performed in spontaneously breathing patients under high flow nasal cannula oxygen
Study NCT03034993 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Text Messaging
Description: Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response.
Study NCT02719275 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social Media Monitoring
Description: Retrospective analyses of social media activity prior to crisis.
Study NCT02063750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strengthening exercises using a Swiss ball
Description: This group performed eight muscle strengthening exercises using a Swiss ball of 65 cm diameter and dumbbells with different loads.~Each training session was 40 minutes long and was performed three times a week for 12 weeks. The exercises were performed in three sets of 12 repetitions, with an interval of one to two minutes of recovery between exercises, which alternated between upper limbs, lower limbs and abdomen. The load used was 60 % of one repetition maximum (1RM).
Study NCT02063750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strengthening exercises
Description: The stretching group performed stretching exercises that targeted the same muscles trained in the IG. The participants remained in the stretched position for three sets of 30 s for each exercise. The total session time was 40 minutes.
Study NCT01184430 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse contour cardiac output device
Description: Goal directed volume therapy using stroke volume variation and cardiac output to guide volume therapy and inotropic support.
Study NCT03266796 — intervention group
Intervention type: BEHAVIORAL
Intervention: goal setting process
Description: goal setting process during the first consultation